DarioHealth Reports Third Quarter 2023 Financial and Operating Results
- Dario's commercial B2B2C revenues increased by 19.3% in Q3 2023 compared to Q3 2022.
- The company is on track to launch its behavioral health platform with Aetna in Q1 2024.
- Dario expanded its relationship with Aetna and an existing regional plan, adding more than $1 million in annual recurring revenues starting in Q1 2024.
- The company expects to add 15 new customers to its platform in Q1 2024.
- Dario announced a new agreement with PlanSource to offer its digital health solutions to more than five million consumers.
- The company ended Q3 2023 with $44 million in cash and cash equivalents.
- None.
- Third quarter total revenue of
$3.52 million $6.6 million $209,000 $3.1 million - Third quarter 2023 commercial B2B2C revenues from monthly recurring revenues derived from employers and health plans is up
19.3% over third quarter 2022; nine months YTD up57% over comparable period in 2022. - Aetna on track to launch its Dario powered behavioral health platform in the first quarter of 2024, with multiple employers already committed to the platform.
- Expanded our relationship with Aetna behavioral health to replace an existing vendor and add more than
$1 million - Expanded our relationship with an existing regional plan from our hypertension solution to now also include diabetes.
- Anticipate adding 15 new customers to Dario's platform in the first quarter of 2024.
- Announced a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology, to offer Dario's full suite of digital health solutions to more than five million consumers.
- Introduced a new GLP-1 Behavioral Change Program to help members realize the transformational power of GLP-1s and other anti-obesity medications while also helping Dario's customers gain better insights on the impact of these medications across their populations.
- Cash and cash equivalents balance as of the end of the third quarter of 2023 of
$44 million - Company to host investor conference call and webcast at 8:30 a.m. ET today.
"As we discussed during our recent investor day, our revenue generally comes from three sources, our historical direct to consumer (B2C) business, recurring revenue from health plans and employers (B2B2C), and strategic revenue from partners like Sanofi
"We ended the quarter in a strong financial position, with
"We achieved a significant win in the third quarter with our expansion of our Aetna business outside of our previously existing contract. We believe this is evidence of our strong Aetna relationship and it expands our footprint within Aetna. Based on our 2023 employer selling season, we anticipate adding at least 15 employers and health plans to Dario's platform in the first quarter of 2024, which includes only new customer business. As evidence of the results our customers are seeing, we anticipate several of our customers will expand our product offering beginning in the first and second quarter of 2024, including two of our existing health plans expanding either the size of the population or lines of business, which will add to our B2B2C revenue growth in the first half of 2024. In addition, we remain only partially penetrated with our large regional plans and MedOne Pharmacy Benefits Solution ("MedOne"), both of which launched in the third quarter of 2023. We expect that we will see increasing revenue from MedOne as it launches its new employers in the first quarter of 2024, and moving into the rest of the year, as Dario is now part of MedOne's standard offering for new customers. We achieved another significant win with our existing regional plans in the third quarter of 2023 as they expanded from hypertension to add diabetes as a condition on their platform. We anticipate that the diabetes program will launch by the first quarter of 2024, and we will see growth in revenue from this customer throughout 2024 as the plan expands its promotion of the program within its population. And, based on our current late-stage pipeline, we anticipate adding several additional health plans in 2024, directly and through partners," stated Rick Anderson, President of Dario. "These includes our partnership with PlanSource Benefits Administration, Inc., under the agreement we announced in the third quarter of 2023, to offer our full suite of digital health solutions to more than five million consumers."
"As we shared during our Investor Day on October 17, 2023, our named strategic partners represent 87 million members which translates to a potential market of about
Q3 2023 and Recent Highlights
- Hosted an in-person investor day on the rise of digital health. The event featured presentations by digital health industry leaders, including Arnaud Robert, respected technology expert and former Head of Digital for Sanofi, Disney and Nike, and Felix Lee,
U.S. Digital Healthcare Medical Head, Sanofi, who explained the rigor and value of the two third party studies of Dario data that were recently presented, including one showing a more than$5,000 - Announced a new strategic partnership with a top five national employee benefits consulting firm to become the preferred digital health and chronic condition solution partner for its national employer clients. The partnership includes Dario's solutions for diabetes, pre-diabetes, hypertension, musculoskeletal and behavioral health.
- Announced a new agreement with PlanSource, a leading provider of cloud-based benefits administration and engagement technology, to offer Dario's full suite of digital health solutions to more than five million consumers.
- Announced a new contract with a large regional health plan through Dario's partnership with Solera. The contract, which launched in late July 2023, will initially offer Dario's hypertension solution to the plan's members. Recently signed an agreement to expand this customer to add Dario's diabetes solution.
- Announced a new contract with pharmacy benefits manager, MedOne, through Dario's strategic partnership with Sanofi. The contract was launched starting with Dario's diabetes solution.
- Introduced a new GLP-1 Behavioral Change Program to help members realize the transformational power of GLP-1s and other anti-obesity medications while also helping Dario's customers gain better insights on the impact of these medications across their populations.
- Announced new research presented by Sanofi at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus demonstrating a
36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes. - Announced new research published in the Journal of Medical Internet Research (JMIR) demonstrating the positive impact of coaching and breathing exercises as part of Dario's behavioral health solution alongside coaching and breathing exercises for members living with depression or anxiety. Among the highlights, the analysis revealed a significant decrease in depression and anxiety symptoms during the first six weeks which was maintained throughout the rest of the 16-week program.
- Presented new research at the ADCES23 Annual Conference demonstrating Dario's ability to sustainably improve health outcomes for users with diabetes over a two-year period. The results showed that during the two years of data analyzed in the research study, users improved engagement
29% over two years. - Announced new research conducted by Sanofi, further demonstrating the economic and clinical value of Dario's platform. The first study demonstrated clinically significant differences in reductions in HbA1c for all Dario users compared to non-users, resulting in a
23.5% reduction in hospitalizations for Dario users. In a separate study, an analysis of matched medical claims revealed$5,077 - Continue to demonstrate the strength of Dario's multi-condition suite, with more than
50% of pipeline opportunities for multi-condition contracts.
Financial Results for the Three Months Ended September 30, 2023:
Revenues for the third quarter ended September 30, 2023, were
Gross profit for the third quarter of 2023 was
Pro-forma gross profit, excluding
Total operating expenses for the third quarter of 2023 were
Operating loss for the third quarter of 2023 was
Operating loss excluding stock-based compensation and depreciation for the third quarter of 2023 was
Net loss was
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the third quarter of 2023 was
Non-GAAP billings for the three months ended September 30, 2023, were
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Nine Months Ended September 30, 2023:
Revenues for the nine months ended September 30, 2023, were
Gross profit for the nine months ended September 30, 2023, was
Pro-forma gross profit, excluding
Total operating expenses for the nine months ended September 30, 2023, were
Total operating expenses excluding stock-based compensation and depreciation for the nine months ended September 30, 2023, were
Operating loss for the nine months ended September 30, 2023, decreased by
Net loss was
Non-GAAP billings for the nine months ended September 30, 2023, were
Non-GAAP adjusted net loss for the nine months ended September 30, 2023, was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, November 2, 8:30am ET
Dial-in: 1-888-886-7786 (domestic) or 1-416-764-8658 (international)
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.
Conference title: DarioHealth Corp. – Third Quarter 2023 Results Call
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1634656&tp_key=1861f55312
Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Saturday, December 2, 2023. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 68054211.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company discusses that it expects to continue to add members to its platform throughout 2023 and 2024, that it anticipates adding 15 new customers to its platform in the first quarter of 2024, the expected timing of certain product launched with its customers, its expectations relating to its expected revenues from certain client contracts, its potential expansion of its relationship with Sanofi, its confidence with respect to the stability of its revenues, its expectation regarding its drive towards increasing its gross margin, the potential growth of its B2B2C business, and its belief that it has barely scratched the surface of what is currently available to it through its existing partnerships, and its large and growing pipeline further supports its confidence in its long-term growth prospects. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expense provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||||
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
Unaudited | ||||||||
ASSETS | ||||||||
CURRENT ASSETS: | ||||||||
Cash and cash equivalents | $ | 43,878 | $ | 49,357 | ||||
Short-term restricted bank deposits | 395 | 165 | ||||||
Trade receivables | 4,533 | 6,416 | ||||||
Inventories | 5,471 | 7,956 | ||||||
Other accounts receivable and prepaid expenses | 1,934 | 1,630 | ||||||
Total current assets | 56,211 | 65,524 | ||||||
NON-CURRENT ASSETS: | ||||||||
Deposits | 5 | 6 | ||||||
Operating lease right of use assets | 978 | 1,206 | ||||||
Long-term assets | 131 | 111 | ||||||
Property and equipment, net | 999 | 788 | ||||||
Intangible assets, net | 6,541 | 9,916 | ||||||
Goodwill | 41,640 | 41,640 | ||||||
Total non-current assets | 50,294 | 53,667 | ||||||
Total assets | $ | 106,505 | $ | 119,191 | ||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||||
September 30, | December 31, | ||||||
2023 | 2022 | ||||||
Unaudited | |||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
CURRENT LIABILITIES: | |||||||
Trade payables | $ | 1,929 | $ | 2,322 | |||
Deferred revenues | 684 | 1,320 | |||||
Operating lease liabilities | 119 | 293 | |||||
Other accounts payable and accrued expenses | 5,374 | 6,592 | |||||
Loan, current | — | 8,823 | |||||
Total current liabilities | 8,106 | 19,350 | |||||
NON-CURRENT LIABILITIES | |||||||
Operating lease liabilities | 804 | 827 | |||||
Long-term loan | 29,000 | 18,105 | |||||
Warrant liability | 524 | 910 | |||||
Other long-term liabilities | 36 | — | |||||
Total non-current liabilities | 30,364 | 19,842 | |||||
STOCKHOLDERS' EQUITY | |||||||
Common stock of | 3 | 3 | |||||
Preferred stock of | *) - | *) - | |||||
Additional paid-in capital | 401,887 | 365,846 | |||||
Accumulated deficit | (333,855) | (285,850) | |||||
Total stockholders' equity | 68,035 | 79,999 | |||||
Total liabilities and stockholders' equity | $ | 106,505 | $ | 119,191 | |||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES
| |||||||||||||
Three months ended | Nine months ended | ||||||||||||
September 30, | September 30, | ||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||
Unaudited | Unaudited | ||||||||||||
Revenues: | |||||||||||||
Services | $ | 1,765 | $ | 4,553 | $ | 11,171 | $ | 12,802 | |||||
Consumer hardware | 1,753 | 2,052 | 5,565 | 8,045 | |||||||||
Total revenues | 3,518 | 6,605 | 16,736 | 20,847 | |||||||||
Cost of revenues: | |||||||||||||
Services | 599 | 1,827 | 3,701 | 3,538 | |||||||||
Consumer hardware | 1,203 | 1,873 | 3,902 | 7,255 | |||||||||
Amortization of acquired intangible assets | 1,106 | 1,105 | 3,281 | 3,131 | |||||||||
Total cost of revenues | 2,908 | 4,805 | 10,884 | 13,924 | |||||||||
Gross profit | 610 | 1,800 | 5,852 | 6,923 | |||||||||
Operating expenses: | |||||||||||||
Research and development | $ | 5,665 | $ | 4,803 | $ | 16,052 | $ | 14,867 | |||||
Sales and marketing | 6,363 | 7,571 | 19,163 | 26,403 | |||||||||
General and administrative | 4,128 | 3,999 | 12,611 | 13,453 | |||||||||
Total operating expenses | 16,156 | 16,373 | 47,826 | 54,723 | |||||||||
Operating loss | 15,546 | 14,573 | 41,974 | 47,800 | |||||||||
Total financial expenses, net | 186 | 1,059 | 3,168 | 1,775 | |||||||||
Loss before taxes | 15,732 | 15,632 | 45,142 | 49,575 | |||||||||
Income Tax | — | — | — | 1 | |||||||||
Net loss | $ | 15,732 | $ | 15,632 | $ | 45,142 | $ | 49,576 | |||||
Other comprehensive loss: | |||||||||||||
Deemed dividend | $ | 1,172 | $ | 494 | $ | 2,863 | $ | 1,378 | |||||
Net loss attributable to shareholders | $ | 16,904 | $ | 16,126 | $ | 48,005 | $ | 50,954 | |||||
Net loss per share: | |||||||||||||
Basic and diluted loss per share of common stock | $ | 0.49 | $ | 0.64 | $ | 1.52 | $ | 2.02 | |||||
Weighted average number of common stock used in | 28,815,604 | 22,973,197 | 28,195,216 | 22,876,397 | |||||||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||||
Nine months ended | |||||||
September 30, | |||||||
2023 | 2022 | ||||||
Unaudited | |||||||
Cash flows from operating activities: | |||||||
Net loss | $ | (45,142) | $ | (49,576) | |||
Adjustments required to reconcile net loss to net cash used in operating activities: | |||||||
Stock-based compensation, common stock, and payment in stock to directors, employees, | 15,307 | 13,898 | |||||
Depreciation | 290 | 243 | |||||
Change in operating lease right of use assets | 228 | (887) | |||||
Amortization of acquired intangible assets | 3,375 | 3,224 | |||||
Decrease (increase) in trade receivables | 1,883 | (3,211) | |||||
Decrease (increase) in other accounts receivable, prepaid expense and long-term assets | (324) | 129 | |||||
Decrease (increase) in inventories | 2,485 | (1,534) | |||||
Decrease in trade payables | (393) | (3,136) | |||||
Decrease in other accounts payable and accrued expenses | (1,182) | (1,401) | |||||
Decrease in deferred revenues | (636) | (205) | |||||
Change in operating lease liabilities | (196) | 800 | |||||
Remeasurement of earn-out | — | 945 | |||||
Non cash financial expenses | 1,267 | 807 | |||||
Net cash used in operating activities | (23,038) | (39,904) | |||||
Cash flows from investing activities: | |||||||
Purchase of property and equipment | (501) | (399) | |||||
Purchase of short-term investments | (4,996) | - | |||||
Proceeds from redemption of short-term investments | 5,033 | - | |||||
Purchase of intangible assets | - | (115) | |||||
Net cash used in investing activities | (464) | (514) | |||||
Cash flows from financing activities: | |||||||
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs | 1,614 | 38,023 | |||||
Proceeds from issuance of preferred stock, net of issuance costs | 14,868 | - | |||||
Proceeds from borrowings on credit agreement | 29,604 | 23,786 | |||||
Repayment of long-term loan | (27,833) | - | |||||
Repurchase and retirement of common stock | - | (134) | |||||
Net cash provided by financing activities | 18,253 | 61,675 | |||||
Increase in cash, cash equivalents and restricted cash and cash equivalents | (5,249) | 21,257 | |||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 49,470 | 35,948 | |||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 44,221 | $ | 57,205 | |||
Supplemental disclosure of cash flow information: | |||||||
Cash paid during the period for interest on long-term loan | $ | 3,035 | $ | 969 | |||
Non-cash activities: | |||||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 14 | $ | 1,177 | |||
Reconciliation of Revenue to Billing (Non-GAAP) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
GAAP Revenue | 3,518 | 6,605 | 16,736 | 20,847 | ||||
Add: | ||||||||
Change in deferred revenue | (105) | (9) | (636) | (205) | ||||
Billing (Non-GAAP) | 3,413 | 6,596 | 16,100 | 20,642 | ||||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Three months ended September 30, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 2,908 | (17) | (1,137) | 1,754 | |||
Gross Profit | 610 | 17 | 1,137 | 1,764 | ||||
Research and development | 5,665 | (1,226) | (22) | 4,417 | ||||
Sales and Marketing | 6,363 | (1,879) | (39) | 4,445 | ||||
General and Administrative | 4,128 | (2,037) | (38) | 2,053 | ||||
Total Operating Expenses | 16,156 | (5,142) | (99) | 10,915 | ||||
Operating Loss | $ | (15,546) | 5,159 | 1,236 | (9,151) | |||
Financing expenses | 186 | - | - | 186 | ||||
Income Tax | - | - | ||||||
Net Loss | $ | (15,732) | 5,159 | 1,236 | (9,337) | |||
Three months ended September 30, 2022 | ||||||||
GAAP | Stock-Based | Earn-out | Non-GAAP | |||||
Cost of Revenues | $ | 4,805 | (25) | (1,132) | 3,648 | |||
Gross Profit | 1,800 | 25 | 1,132 | 2,957 | ||||
Research and development | 4,803 | (1,166) | (12) | 3,625 | ||||
Sales and Marketing | 7,571 | (1,957) | (44) | 5,570 | ||||
General and Administrative | 3,999 | (1,778) | (43) | 2,178 | ||||
Total Operating Expenses | 16,373 | (4,901) | (99) | 11,373 | ||||
Operating Loss | $ | (14,573) | 4,926 | 1,231 | (8,416) | |||
Financing expenses | 1,059 | - | 1,059 | |||||
Income Tax | ||||||||
Net Loss | $ | (15,632) | 4,926 | 1,231 | (9,475) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Nine months ended September 30, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 10,884 | (61) | (3,372) | 7,451 | |||
Gross Profit | 5,852 | 61 | 3,372 | 9,285 | ||||
Research and development | 16,052 | (3,713) | (57) | 12,282 | ||||
Sales and Marketing | 19,163 | (5,550) | (129) | 13,484 | ||||
General and Administrative | 12,611 | (5,983) | (107) | 6,521 | ||||
Total Operating Expenses | 47,826 | (15,246) | (293) | 32,287 | ||||
Operating Loss | $ | (41,974) | 15,307 | 3,665 | (23,002) | |||
Financing expenses | 3,168 | - | - | 3,168 | ||||
Income Tax | - | - | ||||||
Net Loss | $ | (45,142) | 15,307 | 3,665 | (26,170) | |||
Nine months ended September 30, 2022 | ||||||||
GAAP | Stock-Based | Earn-out | Non-GAAP | |||||
Cost of Revenues | $ | 13,924 | (73) | (3,207) | 10,644 | |||
Gross Profit | 6,923 | 73 | 3,207 | 10,203 | ||||
Research and development | 14,867 | (3,214) | (33) | 11,620 | ||||
Sales and Marketing | 26,403 | (5,089) | (348) | 20,966 | ||||
General and Administrative | 13,453 | (5,522) | (824) | 7,107 | ||||
Total Operating Expenses | 54,723 | (13,825) | (1,205) | 39,693 | ||||
Operating Loss | $ | (47,800) | 13,898 | 4,412 | (29,490) | |||
Financing income | 1,775 | - | - | 1,775 | ||||
Income Tax | 1 | 1 | ||||||
Net Loss | $ | (49,576) | 13,898 | 4,412 | (31,266) | |||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
Mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-third-quarter-2023-financial-and-operating-results-301975468.html
SOURCE DarioHealth Corp.
FAQ
What was DarioHealth's total revenue in Q3 2023?
How does Dario's commercial B2B2C revenues in Q3 2023 compare to Q3 2022?
When is Dario expected to launch its behavioral health platform with Aetna?
How many new customers does Dario anticipate adding to its platform in Q1 2024?
What is the value of Dario's new agreement with PlanSource?
What was Dario's cash and cash equivalents balance at the end of Q3 2023?
